A carregar...
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
Rivaroxaban and other oral direct factor Xa inhibitors (ODiXa) are currently developed for prophylaxis and treatment of thromboembolic diseases using fixed doses. Although routine monitoring is not required, assessing the intensity of anticoagulation may be useful under certain clinical conditions....
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3170460/ https://ncbi.nlm.nih.gov/pubmed/21811937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-011-0622-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|